Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription Articles published in Int J Oncol Retrieve available abstracts of 20 articles: HTML format

Single Articles

March 2024
1. GRUNT TW, Wagner R, Ries A, Berghoff AS, et al
   Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells.
   Int J Oncol. 2024;64:24.
   PubMed     Abstract available
   
   
   
2. GENG D, Zhou Y, Wang M
   Advances in the role of GPX3 in ovarian cancer (Review).
   Int J Oncol. 2024;64:31.
   PubMed     Abstract available
   
   
   January 2024
3. LIU Y, Yang Y, Wang X, Yin S, et al
   Function of microRNA?124 in the pathogenesis of cancer (Review).
   Int J Oncol. 2024;64:6.
   PubMed     Abstract available
   
   
   November 2023
4. DENG F, Fu M, Zhao C, Lei J, et al
   Calcium signals and potential therapy targets in ovarian cancer (Review).
   Int J Oncol. 2023;63:125.
   PubMed     Abstract available
   
   
   October 2023
5. YUAN J, Guan W, Li X, Wang F, et al
   RBM15‑mediating MDR1 mRNA m(6)A methylation regulated by the TGF‑beta signaling pathway in paclitaxel‑resistant ovarian cancer.
   Int J Oncol. 2023;63:112.
   PubMed     Abstract available
   
   
   May 2023
6. CHEN Q, Shen S, Lv N, Tong J, et al
   Role of microRNAs in glycolysis in gynecological tumors (Review).
   Int J Oncol. 2023;62:63.
   PubMed     Abstract available
   
   
   December 2022
7. KARIN-KUJUNDZIC V, Covarrubias-Pinto A, Skrtic A, Vranic S, et al
   New insight into the role of PTCH1 protein in serous ovarian carcinomas.
   Int J Oncol. 2022;61.
   PubMed     Abstract available
   
   
   October 2022
8. WANG Y, Han A, Chen E, Singh RK, et al
   [Corrigendum] The cranberry flavonoids PAC DP9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells.
   Int J Oncol. 2022;61.
   PubMed     Abstract available
   
   
   
9. LI R, Wang Y, Xu Y, He X, et al
   [Retracted] Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression.
   Int J Oncol. 2022;61.
   PubMed     Abstract available
   
   
   
10. BJERSAND K, Blom K, Poromaa IS, Stalberg K, et al
    Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    
11. KIM SH, Baek KH
    Ovarian tumor deubiquitinase 6A regulates cell proliferation via deubiquitination of nucleolin and caspase7.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    July 2022
12. FEDIER A, Maggi N, Tozzi A, Disler M, et al
    Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Int J Oncol. 2022;61.
    PubMed     Abstract available
    
    
    May 2022
13. ZHANG R, Roque DM, Reader J, Lin J, et al
    Combined inhibition of IL6 and IL8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    
14. LAVORO A, Scalisi A, Candido S, Zanghi GN, et al
    Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    March 2022
15. SINGH T, Neal A, Dibernardo G, Raheseparian N, et al
    Efficacy of birinapant in combination with carboplatin in targeting platinumresistant epithelial ovarian cancers.
    Int J Oncol. 2022;60.
    PubMed     Abstract available
    
    
    July 2021
16. CHAUVIN M, Garambois V, Choblet S, Colombo PE, et al
    Anti-Mullerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
    Int J Oncol. 2021;59.
    PubMed     Abstract available
    
    
    
17. FALZONE L, Scandurra G, Lombardo V, Gattuso G, et al
    A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).
    Int J Oncol. 2021;59.
    PubMed     Abstract available
    
    
    May 2021
18. THONGCHOT S, Jamjuntra P, Therasakvichya S, Warnnissorn M, et al
    Interleukin8 released by cancerassociated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.
    Int J Oncol. 2021;58.
    PubMed     Abstract available
    
    
    September 2020
19. LIU J, Liu D, Liu JJ, Zhao C, et al
    [Corrigendum] Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2020 Sep 28. doi: 10.3892/ijo.2020.5129.
    PubMed     Abstract available
    
    
    April 2020
20. GUO F, Zhang K, Li M, Cui L, et al
    miR5083p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.
    Int J Oncol. 2020 Apr 27. doi: 10.3892/ijo.2020.5055.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.